| Metabolic stress is a barrier to Epstein–Barr virus-mediated B-cell immortalization K McFadden, AY Hafez, R Kishton, JE Messinger, PA Nikitin, JC Rathmell, ... Proceedings of the National Academy of Sciences 113 (6), E782-E790, 2016 | 125 | 2016 |
| Monocarboxylate transporter antagonism reveals metabolic vulnerabilities of viral-driven lymphomas EN Bonglack, JE Messinger, JM Cable, J Ch’ng, KM Parnell, ... Proceedings of the National Academy of Sciences 118 (25), e2022495118, 2021 | 45 | 2021 |
| c-Myc represses transcription of Epstein-Barr virus latent membrane protein 1 early after primary B cell infection AM Price, JE Messinger, MA Luftig Journal of virology 92 (2), 10.1128/jvi. 01178-17, 2018 | 38 | 2018 |
| Limited nucleotide pools restrict Epstein–Barr virus-mediated B-cell immortalization AY Hafez, JE Messinger, K McFadden, G Fenyofalvi, CN Shepard, ... Oncogenesis 6 (6), e349-e349, 2017 | 33 | 2017 |
| Identification of host biomarkers of epstein-barr virus latency IIb and latency III JE Messinger, J Dai, LJ Stanland, AM Price, MA Luftig MBio 10 (4), 10.1128/mbio. 01006-19, 2019 | 24 | 2019 |
| Chlamydia Infection Across Host Species Boundaries Promotes Distinct Sets of Transcribed Anti-Apoptotic Factors JE Messinger, E Nelton, C Feeney, DC Gondek Frontiers in cellular and infection microbiology 5, 96, 2015 | 12 | 2015 |
| Limited nucleotide pools restrict Epstein-Barr virus-mediated B-cell immortalization. Oncogenesis. 2017; 6 (6): e349 AY Hafez, JE Messinger, K McFadden, G Fenyofalvi, CN Shepard, ... Epub 2017/06/13. https://doi. org/10.1038/oncsis. 2017.46 PMID: 28604764, 0 | 5 | |
| Evaluation of host cellular responses to Epstein–Barr virus (EBV) in adult lung transplant patients with EBV‐associated diseases L Zaffiri, JE Messinger, EJ Bush, JS Staats, P Patel, SM Palmer, ... Journal of medical virology 95 (4), e28724, 2023 | 2 | 2023 |
| Transcriptomic and Metabolic Heterogeneity During Epstein-Barr Virus Latency Establishment JE Messinger Duke University, 2019 | 1 | 2019 |
| Development of a novel ddPCR assay for nonclinical and clinical pharmacokinetic characterization of ICVB-1042. N Rice, J Price, J Field, Y Kato, J Messinger, M Pokrass, J Maltzman, ... Journal of Clinical Oncology 41 (16_suppl), e14693-e14693, 2023 | | 2023 |
| Characterizing the tumor selectivity of oncolytic adenovirus ICVB-1042: Analysis of S-phase induction, viral replication, and cytolytic activity in human primary normal cell types. M Pokrass, P Rosenthal, J Messinger, R Rodriguez, H Nowyhed Journal of Clinical Oncology 41 (16_suppl), e14503-e14503, 2023 | | 2023 |
| ICVB-1042, an oncolytic adenovirus, infects and kills bladder, breast, and glioblastoma human dissociated tumor cells M Pokrass, P Rosenthal, J Messinger, J Field, H Nowyhed Cancer Research 83 (7_Supplement), 681-681, 2023 | | 2023 |
| 1362 Nonclinical characterization of ICVB-1042, a novel E2F-tumor selective oncolytic virus with the potential to treat solid tumors M Lyman, J Field, J Messinger, N Rice, M Lanahan, A Kato, M Pokrass, ... Journal for ImmunoTherapy of Cancer 10 (Suppl 2), 2022 | | 2022 |
| 1216 The chimeric Ad5/Ad34 fiber of ICVB-1042 oncolytic virus requires the CD46 cell surface receptor for efficient tumor entry M Pokrass, P Rosenthal, J Messinger, N Rice, H Nowyhed Journal for ImmunoTherapy of Cancer 10 (Suppl 2), 2022 | | 2022 |
| Evaluation of Host Immune Responses to Epstein-Barr Virus in Lung Transplant Recipients L Zaffiri, JE Messinger, J Yi, KJ Weinhold, G Ferrari, M Luftig, SM Palmer AMERICAN JOURNAL OF TRANSPLANTATION 20, 396-396, 2020 | | 2020 |
